Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization

被引:16
作者
Kollaritsch, H
Cryz, SJ
Lang, AB [1 ]
Herzog, C
Que, JU
Wiedermann, G
机构
[1] Swiss Serum & Vaccine Inst, CH-3001 Bern, Switzerland
[2] Univ Vienna, Inst Specif Prophylaxis & Trop Med, A-1095 Vienna, Austria
关键词
S. typhi Ty21a; V. cholerae CVD103-HgR; vaccine;
D O I
10.1016/S0264-410X(00)00101-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The local and systemic antibody responses elicited following concomitant primary immunization and reimmunization with the live oral attenuated Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a vaccine strains were determined in healthy adult volunteers. A more pronounced serum vibriocidal antibody response was generated after primary immunization compared to reimmunization 2.5 or 3.5 yr later. The seroconversion rate (greater than or equal to 4-fold rise over baseline) was 81% subsequent to primary immunization versus 57% (p = 0.018) and 65% (p = 0.639) upon reimmunization at 2.5 and 3.5 yr, respectively. A similar trend was observed for serum anti-S. typhi lipopolysaccharide (LPS) antibodies. After primary immunization, 48% of subjects manifested a significant rise in coproantibody levels to V. cholerae LPS while 60% did so for cholera toxin (CT). Upon reimmunization, the response rate for LPS ranged from 38% at 2.5 yr to 56% at 3.5 yr (p > 0.05), while that for CT varied from 31% (p = 0.007) to 50% (p = 0.541) at 2.5 and 3.5 yr, respectively. The anti-g. typhi IgA coproantibody response rate was 70% subsequent to primary immunization versus 47% at 2.5 yr (p = 0.021) and 63% at 3.5 yr (p = 0.77). (C) 2000 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3031 / 3039
页数:9
相关论文
共 28 条
[1]   DEMONSTRATION OF SPECIFIC IGA IN HUMAN FECES AFTER IMMUNIZATION WITH LIVE TY21A SALMONELLA-TYPHI VACCINE [J].
CANCELLIERI, V ;
FARA, GM .
JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (03) :482-484
[2]   FIELD TRIAL OF ORAL CHOLERA VACCINES IN BANGLADESH - SERUM VIBRIOCIDAL AND ANTITOXIC ANTIBODIES AS MARKERS OF THE RISK OF CHOLERA [J].
CLEMENS, JD ;
VANLOON, F ;
SACK, DA ;
CHAKRABORTY, J ;
RAO, MR ;
AHMED, F ;
HARRIS, JR ;
KHAN, MR ;
YUNUS, M ;
HUDA, S ;
KAY, BA ;
SVENNERHOLM, AM ;
HOLMGREN, J .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1235-1242
[3]   SAFETY AND IMMUNOGENICITY OF SALMONELLA-TYPHI TY21A VACCINE IN YOUNG THAI CHILDREN [J].
CRYZ, SJ ;
VANPRAPAR, N ;
THISYAKORN, U ;
OLANRATMANEE, T ;
LOSONSKY, G ;
LEVINE, MM ;
CHEARSKUL, S .
INFECTION AND IMMUNITY, 1993, 61 (03) :1149-1151
[4]   SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF VIBRIO-CHOLERAE CVD-103-HGR LIVE ORAL CHOLERA VACCINE IN SWISS ADULTS [J].
CRYZ, SJ ;
LEVINE, MM ;
LOSONSKY, G ;
KAPER, JB ;
ALTHAUS, B .
INFECTION AND IMMUNITY, 1992, 60 (09) :3916-3917
[5]   SAFETY AND IMMUNOGENICITY OF A LIVE ORAL BIVALENT TYPHOID-FEVER (SALMONELLA-TYPHI TY21A) CHOLERA (VIBRIO-CHOLERAE CVD 103-HGR) VACCINE IN HEALTHY-ADULTS [J].
CRYZ, SJ ;
QUE, JU ;
LEVINE, MM ;
WIEDERMANN, G ;
KOLLARITSCH, H .
INFECTION AND IMMUNITY, 1995, 63 (04) :1336-1339
[6]   COMPARATIVE-ANALYSIS OF IMMUNOLOGICAL RESPONSES TO ORAL (TY21A) AND PARENTERAL (TAB) TYPHOID VACCINES [J].
DAMELIO, R ;
TAGLIABUE, A ;
NENCIONI, L ;
DIADDARIO, A ;
VILLA, L ;
MANGANARO, M ;
BORASCHI, D ;
LEMOLI, S ;
NISINI, R ;
MATRICARDI, PM .
INFECTION AND IMMUNITY, 1988, 56 (10) :2731-2735
[7]   LIVE ORAL CHOLERA VACCINE - A PRELIMINARY REVIEW OF ITS PHARMACOLOGY AND CLINICAL POTENTIAL IN PROVIDING PROTECTIVE IMMUNITY AGAINST CHOLERA [J].
DAVIS, R ;
SPENCER, CM .
CLINICAL IMMUNOTHERAPEUTICS, 1995, 4 (03) :235-247
[8]   EFFECT OF PARENTERAL IMMUNIZATION ON THE INTESTINAL IMMUNE-RESPONSE TO SALMONELLA-TYPHI TY21A [J].
FORREST, BD ;
LABROOY, JT ;
DEARLOVE, CE ;
SHEARMAN, DJC .
INFECTION AND IMMUNITY, 1992, 60 (02) :465-471
[9]   SEROEPIDEMIOLOGICAL STUDIES OF EL-TOR CHOLERA IN BANGLADESH - ASSOCIATION OF SERUM ANTIBODY-LEVELS WITH PROTECTION [J].
GLASS, RI ;
SVENNERHOLM, AM ;
KHAN, MR ;
HUDA, S ;
HUQ, MI ;
HOLMGREN, J .
JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (02) :236-242
[10]   SAFETY, IMMUNOGENICITY, AND EXCRETION PATTERN OF SINGLE-DOSE LIVE ORAL CHOLERA VACCINE CVD 103-HGR IN PERUVIAN ADULTS OF HIGH AND LOW SOCIOECONOMIC LEVELS [J].
GOTUZZO, E ;
BUTRON, B ;
SEAS, C ;
PENNY, M ;
RUIZ, R ;
LOSONSKY, G ;
LANATA, CF ;
WASSERMAN, SS ;
SALAZAR, E ;
KAPER, JB ;
CRYZ, S ;
LEVINE, MM .
INFECTION AND IMMUNITY, 1993, 61 (09) :3994-3997